Evidence map›Paper›PMID 37765685›Full record

ArticlePolymers2023

Screening of Oligomeric (Meth)acrylate Vaccine Adjuvants Synthesized via Catalytic Chain Transfer Polymerization.

Cordula S Hege, Amy Stimpson, Joseph Sefton, James Summers, Helena Henke, Adam A Dundas, Tony Phan, Robert Kinsey, Jeffrey A Guderian, Sandra J Sivananthan and 6 more

Abstract read
In one paragraph

Article in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cordula S HegeCentre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK.
Amy StimpsonCentre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK.
Joseph SeftonCentre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK.
James SummersSchool of Chemistry, University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0009-0006-3985-8874
Helena HenkeCentre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0002-2068-1910
Adam A DundasCentre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0002-7532-5374
Tony PhanAccess to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA.
Robert KinseyAccess to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA.
Jeffrey A GuderianAccess to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA.
Sandra J SivananthanAccess to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA.
Raodoh MohamathAccess to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA.
William R LykinsAccess to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA.
Gabi Ramer-DenisoffAccess to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA.
Susan LinAccess to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA.
Christopher B FoxAccess to Advanced Health Institute, Formerly Infectious Disease Research Institute, Seattle, WA 98102, USA.
Derek J IrvineCentre for Additive Manufacturing, Department of Chemical and Environmental Engineering, University of Nottingham, Nottingham NG7 2RD, UK.

Funding

Engineering sustainable squalene analogues for novel vaccine adjuvant emulsionsR01AI135673 · NIAID · ACCESS TO ADVANCED HEALTH INSTITUTE · PI FOX, CHRISTOPHER B · 2018 to 2022
$4.1M
NIAID NIH HHS R01 AI135673
6 · The paper itself

Abstract

This report details the first systematic screening of free-radical-produced methacrylate oligomer reaction mixtures as alternative vaccine adjuvant components to replace the current benchmark compound squalene, which is unsustainably sourced from shark livers. Homo-/co-oligomer mixtures of methyl, butyl, lauryl, and stearyl methacrylate were successfully synthesized using catalytic chain transfer control, where the use of microwave heating was shown to promote propagation over chain transfer. Controlling the mixture material properties allowed the correct viscosity to be achieved, enabling the mixtures to be effectively used in vaccine formulations. Emulsions of selected oligomers stimulated comparable cytokine levels to squalene emulsion when incubated with human whole blood and elicited an antigen-specific cellular immune response when administered with an inactivated influenza vaccine, indicating the potential utility of the compounds as vaccine adjuvant components. Furthermore, the oligomers' molecular sizes were demonstrated to be large enough to enable greater emulsion stability than squalene, especially at high temperatures, but are predicted to be small enough to allow for rapid clearance from the body.

Indexed as

adjuvantcatalytic chain transferpolymerizationscreeningsqualenevaccine

Identifiers

PMID37765685
PMCPMC10538096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.